Summarised characteristics of patients with non-cystic fibrosis bronchiectasis
| Gender (male:female) | 13:28 | |
| Range | Mean (± SD) | |
| Age (years) | 37–74 | 62.9 (± 6.9) |
| FEV1% pre bronchodilator | 35–102 | 72.9 (± 15.3) |
| FEV1% post bronchodilator | 41–104 | 76.8 (± 14.4) |
| Duration of bronchiectasis (years) | 4–70 | 40.7 (± 22.9) |
| Pulmonary exacerbations reported in the preceding 12 months (n) | 2–12 | 5.0 (±2.8) |
| LCS | 5.5–20 | 14.2 (± 4.0) |
| SGRQ total | 19–80 | 39.4 (± 16.4) |
| SGRQ symptoms | 24–100 | 59.8 (± 20.9) |
| C-reactive protein (mg/litre) | 0–18 | 4.7 (± 4.8) |
| Sputum neutrophils (×105/ml) | 56–611 | 382.8 (± 122.3) |
| Sputum % neutrophils | 39–99 | 83.7 (± 15.3) |
| Pseudomonas aeruginosa positive (standard culture)* | 27% (11 of 41) | |
| Haemophilus influenzae positive (standard culture)* | 29% (12 of 41) | |
| ICS use | ||
| Alone | 12% (5 of 41) | |
| In combination with LABA | 44% (18 of 41) |
Of the 41 subjects, 40 were Caucasian and one was Maori.
*Standard diagnostic microbiology performed on separate sample to that used for molecular analysis.
FEV1%, forced expiratory volume in 1 s as a percentage of the predicted value; ICS, inhaled corticosteroid; LABA, long-acting β agonist; LCS, Leicester Cough Score, lower scores indicate worse cough symptoms, range 3–21; SGRQ, St George's Respiratory Questionnaire—range 1–100, lower scores indicate better quality of life, symptoms component measures the effect of respiratory symptoms; sputum % neutrophils, neutrophils in induced sputum as a percent of total non-squamous cells.